The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Subscribe To Our Newsletter & Stay Updated
